Answers are grounded in this paper and cite their sources.
OBJECTIVES: During the last decade many new biological immune modulators have entered the market as new therapeutic principles. Tumor necrosis factor (TNF)-α is a pro-inflammatory cytokine known to a have a key role in the pathogenic mechanisms of various immune-mediated or inflammatory diseases. However, TNF-α also plays a key role in endothelial dysfunction and, thus, in the development and progression of atherosclerosis. What, then, is the potential therapeutic role of TNF-α inhibitors? METHODS: We analysed the current literature concerning the administration of TNF-α inhibitors and their potential benefits upon endothelial function. RESULTS: TNF-α inhibitors decrease the serum levels of inflammatory markers such as TNF-α itself, CRP, IL-6, and increased the tissue expression of endothelial NO synthase and the vasodilatory response to bradykinin. DISCUSSION: TNF-α inhibitors may change the progression of endothelial dysfunction and, thus, slow down the atherosclerotic process.
No takes yet. Share an insight, caveat, or question.
Murdaca et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: